SuperworthVeracyte profit margin VCYT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- 20.4%
- Operating margin, 12 months
- 18.8%
- Net margin on a year earlier
- +14.9 pts
- Peer median
- 9.3%
Over the twelve months to Jun 30, 2026, Veracyte kept 20.4% of its revenue as net profit, with an operating margin of 18.8% and a gross margin of 71.7%.
Five years earlier its net margin was −40.1%.
The median for 10 diagnostics and research stocks of a similar size is 9.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 12.8% | 11.2% | 70.1% |
| FY2024 | 5.4% | 3.6% | 66.9% |
| FY2023 | −20.6% | −23.8% | 66.1% |
| FY2022 | −12.3% | −13.9% | 65.7% |
| FY2021 | −34.4% | −37.3% | 66.1% |
| FY2020 | −29.7% | −30.1% | 64.7% |
| FY2019 | −10.5% | −12.6% | 69.7% |
| FY2018 | −25.0% | −24.2% | 64.0% |
| FY2017 | −43.1% | −36.9% | 60.8% |
| FY2016 | −48.2% | −44.3% | 60.9% |
| FY2015 | −68.1% | −67.6% | 56.6% |
| FY2014 | −76.9% | −76.0% | 56.5% |
| FY2013 | n/a | n/a | 42.4% |
| FY2012 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 20.4% | +14.9 pts | 18.8% | |
| Q1 FY26 | 16.2% | +9.1 pts | 14.3% | |
| Q4 FY25 | 12.8% | +7.4 pts | 11.2% | |
| Q3 FY25 | 6.1% | +8.3 pts | 5.0% | |
| Q2 FY25 | 5.5% | +19.0 pts | 2.9% | |
| Q1 FY25 | 7.1% | +25.3 pts | 5.1% | |
| Q4 FY24 | 5.4% | +26.0 pts | 3.6% | |
| Q3 FY24 | −2.2% | +12.4 pts | −5.5% | |
| Q2 FY24 | −13.5% | −4.7 pts | −16.8% | |
| Q1 FY24 | −18.2% | −8.5 pts | −21.3% | |
| Q4 FY23 | −20.6% | −8.3 pts | −23.8% | |
| Q3 FY23 | −14.6% | +0.7 pts | −16.2% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.
| Company | Profit margin |
|---|---|
| VCYTVeracyte | 20.4% |
| CDNACareDx | 24.2% |
| BLLNBillionToOne | 9.5% |
| LNTHLantheus | 17.7% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| NRCNRC Health | 4.2% |
| Peer median | 9.3% |
Where Veracyte ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Veracyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.